
Paradigm Health Goes Live With Amgen and AstraZeneca Trials Simultaneously, Exposing Partners to Catastrophic Data Risk
Paradigm Health's Study Conduct platform launched simultaneously hosting Phase 1b and Phase 2 clinical trials for Amgen and AstraZeneca. Operational failures — including data loss, EHR integration outages, or algorithmic misclassification — could invalidate trial data and trigger liability from both pharma partners. The concurrent launch amplifies risk exposure at a moment when the platform has no live track record.




